3) Drive though what are recommended ontologies to use for core entities, to help persuade consortia/centres to use these. Number one is that they actually use something controlled in the first place, some like Encode are very good. We may need to focus on a few transcriptomics datasets from say 2 diverse consortia. Opportunity for a paper?
MIAME and MIAPI do identify minimal metadata entities. However, there is much leniency around the reference metadata for different entities.
Core entities include sample(species, tissue, cell type, cell line, disease/normal) , treatment(stimulant, dosage, compound etc.) etc.
3) Drive though what are recommended ontologies to use for core entities, to help persuade consortia/centres to use these. Number one is that they actually use something controlled in the first place, some like Encode are very good. We may need to focus on a few transcriptomics datasets from say 2 diverse consortia. Opportunity for a paper?
MIAME and MIAPI do identify minimal metadata entities. However, there is much leniency around the reference metadata for different entities. Core entities include sample(species, tissue, cell type, cell line, disease/normal) , treatment(stimulant, dosage, compound etc.) etc.
Owner: Peter Woollard (GSK)